Faraone S
Neurosci Biobehav Rev. 2018; 87:255-270.
PMID: 29428394
PMC: 8063758.
DOI: 10.1016/j.neubiorev.2018.02.001.
Sibley D, Weinberger S, Segal D, Creese I
Experientia. 1982; 38(10):1224-5.
PMID: 6890464
DOI: 10.1007/BF01959753.
Kokkinidis L, MacNeill E
Psychopharmacology (Berl). 1982; 78(4):331-5.
PMID: 6818594
DOI: 10.1007/BF00433736.
Rebec G, Peirson E, McPherson F, Brugge K
Psychopharmacology (Berl). 1982; 77(4):360-6.
PMID: 6813898
DOI: 10.1007/BF00432771.
Riffee W, Wilcox R, Vaughn D, Smith R
Psychopharmacology (Berl). 1982; 77(2):146-9.
PMID: 6812131
DOI: 10.1007/BF00431937.
Sensitization of mice to methylphenidate.
Shuster L, Hudson J, Anton M, Righi D
Psychopharmacology (Berl). 1982; 77(1):31-6.
PMID: 6812116
DOI: 10.1007/BF00436096.
Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol.
Seeger T, Thal L, Gardner E
Psychopharmacology (Berl). 1982; 76(2):182-7.
PMID: 6805029
DOI: 10.1007/BF00435275.
Enhancement of haloperidol-induced increase in rat striatal or mesolimbic 3,4-dihydroxyphenylacetic acid and homovanillic acid by pretreatment with chronic methamphetamine.
Toru M, Mataga N, Takashima M, Nishikawa T
Psychopharmacology (Berl). 1981; 74(4):316-20.
PMID: 6794073
DOI: 10.1007/BF00432738.
Effect of chronic amphetamine administration on central dopaminergic mechanisms in the vervet.
Owen F, Baker H, Ridley R, Cross A, Crow T
Psychopharmacology (Berl). 1981; 74(3):213-6.
PMID: 6791228
DOI: 10.1007/BF00427096.
Use of the intracerebral injection technique to elucidate mechanisms of apomorphine climbing and its antagonism in the mouse.
Costall B, Naylor R, Nohria V
Psychopharmacology (Berl). 1981; 73(1):91-4.
PMID: 6785798
DOI: 10.1007/BF00431110.
The behavioral and biochemical effects of lithium on dopaminergic agonist-induced supersensitivity.
Rubin E, Wooten G
Psychopharmacology (Berl). 1984; 84(2):217-20.
PMID: 6438680
DOI: 10.1007/BF00427448.
Reduction of 3H-spiroperidol binding in rat striatum and frontal cortex by chronic amphetamine: dose response, time course and role of sustained dopamine release.
Nielsen E, Nielsen M, Braestrup C
Psychopharmacology (Berl). 1983; 81(1):81-5.
PMID: 6415736
DOI: 10.1007/BF00439279.
Brain locations controlling the behavioral effects of chronic amphetamine intoxication.
Hitzemann R, Wu J, Hom D, Loh H
Psychopharmacology (Berl). 1980; 72(1):93-101.
PMID: 6162168
DOI: 10.1007/BF00433812.
Behavioural tolerance to amphetamine and other psychostimulants: the case for considering behavioural mechanisms.
Demellweek C, Goudie A
Psychopharmacology (Berl). 1983; 80(4):287-307.
PMID: 6137855
DOI: 10.1007/BF00432109.
Differential effects of chronic treatment with chlorpromazine versus cocaine on behavioral responsiveness to nigral GABA receptor stimulation.
Bachus S, Gale K
Psychopharmacology (Berl). 1988; 95(1):56-62.
PMID: 2838860
DOI: 10.1007/BF00212767.
D-2 but not D-1 dopamine agonists produce augmented behavioral response in rats after subchronic treatment with methamphetamine or cocaine.
Ujike H, Akiyama K, Otsuki S
Psychopharmacology (Berl). 1990; 102(4):459-64.
PMID: 2151400
DOI: 10.1007/BF02247125.
Effects of subchronic amphetamine or amfonelic acid on rat brain dopaminergic and serotonergic function.
McMILLEN B, Scott S, Williams H
J Neural Transm Gen Sect. 1991; 83(1-2):55-66.
PMID: 2018630
DOI: 10.1007/BF01244452.
